Precipio stock reports 24.18 percent sales growth but posts a loss
Published on 09/30/2026 at 12:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Precipio stock generated USD 7.021 million in second-quarter 2026 revenue, up 24.18 percent from USD 5.654 million a year earlier. The quarter also brought a USD 219,000 net loss, giving investors a clear split between expanding sales and still-negative earnings.
Revenue growth meets earnings pressure
According to ScanX News, Precipio reported the USD 7.021 million sales figure for Q2 2026, compared with USD 5.654 million in Q2 2025. The same report shows diluted earnings per share of minus USD 0.12, versus positive USD 0.05 in the prior-year quarter.
The earnings profile therefore remained weaker than the top line. Revenue growth was accompanied by a swing from profit to loss, making cost control and operating leverage central issues for the next report.
Product revenue gains scale
The Globe and Mail reported that product revenue reached USD 906,000 in Q2 2026, up 45.2 percent from USD 624,000 a year earlier. Service revenue rose 21.6 percent to USD 6.1 million, while gross profit increased 29.1 percent to USD 3.1 million and gross margin reached 45 percent.
Operating activity also expanded. Precipio processed 4,652 diagnostic cases in the quarter, 26 percent more than the 3,692 cases recorded in the comparable period, linking laboratory volume growth with the increase in service revenue.
Nasdaq value and Q2 cash
PRPO was last at USD 23.58 on Nasdaq on September 29, 2026 at 4:00 p.m. ET. Its market capitalization was USD 42.1 million on that date, while the 52-week range stood at USD 16.40 to USD 33.63.
Cash stood at USD 3.075 million on June 30, 2026, up from USD 2.604 million on March 31, 2026. Operating cash flow reached USD 660,000 in Q2, compared with USD 64,000 in Q1, providing a measurable improvement in internal funding during the first half of 2026.
Precipio stock facts
- Company: Precipio, Inc.
- Ticker: PRPO
- Primary exchange: Nasdaq
- Market capitalization: USD 42.1 million as of September 29, 2026
- 52-week range: USD 16.40-33.63 as of September 29, 2026
- Sector / Industry: Healthcare / Laboratory Analytical Instruments
